Natixis Advisors LLC Sells 146,232 Shares of The Chemours Company (NYSE:CC)

Natixis Advisors LLC lessened its holdings in shares of The Chemours Company (NYSE:CC) by 27.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 377,973 shares of the specialty chemicals company’s stock after selling 146,232 shares during the quarter. Natixis Advisors LLC’s holdings in Chemours were worth $7,680,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Mitsubishi UFJ Trust & Banking Corp raised its holdings in shares of Chemours by 169.3% in the 1st quarter. Mitsubishi UFJ Trust & Banking Corp now owns 35,105 shares of the specialty chemicals company’s stock worth $1,009,000 after acquiring an additional 22,067 shares during the last quarter. Khrom Capital Management LLC lifted its holdings in shares of Chemours by 54.6% in the second quarter. Khrom Capital Management LLC now owns 3,456,626 shares of the specialty chemicals company’s stock valued at $78,016,000 after purchasing an additional 1,220,967 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of Chemours during the first quarter valued at approximately $1,764,000. Point72 Hong Kong Ltd bought a new stake in Chemours during the second quarter worth $789,000. Finally, Jade Capital Advisors LLC raised its position in Chemours by 75.0% in the 3rd quarter. Jade Capital Advisors LLC now owns 70,000 shares of the specialty chemicals company’s stock valued at $1,422,000 after buying an additional 30,000 shares during the last quarter. Institutional investors and hedge funds own 76.26% of the company’s stock.

Chemours Price Performance

Chemours stock opened at $20.83 on Friday. The company has a current ratio of 1.73, a quick ratio of 0.92 and a debt-to-equity ratio of 6.05. The business’s 50 day simple moving average is $19.32 and its 200 day simple moving average is $21.61. The Chemours Company has a 12 month low of $15.10 and a 12 month high of $32.70. The company has a market cap of $3.11 billion, a price-to-earnings ratio of 41.65 and a beta of 1.75.

Chemours (NYSE:CC) last announced its quarterly earnings data on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.32 by $0.08. The business had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.44 billion. Chemours had a return on equity of 29.48% and a net margin of 1.34%. The firm’s quarterly revenue was up .9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.64 EPS. Sell-side analysts forecast that The Chemours Company will post 1.35 EPS for the current year.

Chemours Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Friday, November 15th will be issued a $0.25 dividend. This represents a $1.00 annualized dividend and a yield of 4.80%. The ex-dividend date of this dividend is Friday, November 15th. Chemours’s dividend payout ratio (DPR) is presently 200.00%.

Insider Activity at Chemours

In other news, SVP Alvenia Scarborough sold 7,500 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $20.64, for a total value of $154,800.00. Following the completion of the transaction, the senior vice president now directly owns 16,645 shares in the company, valued at approximately $343,552.80. This trade represents a 31.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.47% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms have issued reports on CC. UBS Group cut their price objective on shares of Chemours from $30.00 to $28.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. The Goldman Sachs Group cut their price target on shares of Chemours from $29.00 to $23.00 and set a “neutral” rating on the stock in a report on Tuesday, September 3rd. Royal Bank of Canada decreased their price objective on shares of Chemours from $28.00 to $25.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. JPMorgan Chase & Co. reduced their target price on Chemours from $25.00 to $18.00 and set a “neutral” rating for the company in a report on Tuesday, August 6th. Finally, BMO Capital Markets lifted their price target on Chemours from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, October 7th. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $24.88.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.